Back to top
more

Surmodics (SRDX)

(Delayed Data from NSDQ)

$41.80 USD

41.80
478,250

+0.02 (0.05%)

Updated Jul 23, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Here's Why You Should Retain Surmodics (SRDX) Stock for Now

Surmodics (SRDX) is gaining from continued strength at Medical Devices unit and persistent efforts to boost R&D functionalities. However, weak performance at Surmodics' IVD unit remains a concern.

Here's Why You Should Hold on to Surmodics (SRDX) Stock Now

Surmodics (SRDX) is gaining from continued strength at Medical Devices unit and persistent efforts to boost R&D functionalities. However, weak performance at Surmodics' IVD unit remains a concern.

Surmodics (SRDX) Q4 Earnings and Revenues Beat Estimates

Surmodics (SRDX) continues to gain from core Medical Devices unit, which saw significant contribution from the SurVeil deal with Abbott in Q4.

SurModics (SRDX) Q4 Earnings and Revenues Surpass Estimates

SurModics (SRDX) delivered earnings and revenue surprises of 5.71% and 8.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

LabCorp (LH) Q3 Earnings Surpass Estimates, Tapers View

LabCorp (LH) impresses investors with third-quarter 2019 results on the robust performance of the Covance Drug Development segment.

Here's Why You Should Hold on to Abbott (ABT) Stock for Now

Investors continue to be optimistic about Abbott's (ABT) performance.

ResMed Upgrades Nasal Care by Introducing Cradle CPAP Mask

ResMed (RMD) revolutionizes sleep apnea treatment by introducing a hassle-free and easy-to-use mask.

Trina Mukherjee headshot

Medical Products Industry Outlook: Prospects Seem Promising

Growth prospects look bright for the Zacks Medical Products industry, thanks to AI, Medical Mechatronics and Robotics and rampant M&As.

Here's Why You Should Hold on to Chemed (CHE) Stock Right Now

Investors continue to be optimistic about Chemed's (CHE) performance.

Organigram (OGI) Catches Eye: Stock Jumps 8.6%

Organigram (OGI) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Here's Why You Should Invest in Surmodics (SRDX) Stock Now

Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.

Top Ranked Momentum Stocks to Buy for September 26th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, September 26th

Will SurModics (SRDX) Gain on Rising Earnings Estimates?

SurModics (SRDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Nalak Das headshot

Wall Street Bulls Roaring Despite Slowdown Fears: 5 Top Picks

Year to date, the performance on Wall Street is projecting a glorious picture with no end to the bull run in sight, at least this year.

Stryker's Mobius Imaging Buyout to Boost Its Spine Division

Stryker (SYK) expects the buyout to remain neutral to its 2019 earnings.

Here's Why You Should Invest in Surmodics (SRDX) Stock Now

Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.

Haemonetics (HAE) Beats on Q1 Earnings, Raises '19 EPS View

Haemonetics (HAE) Q1 performance by all business sections has been impressive, except for BloodCenter.

BioScrip Closes Option Care Merger, Incurs Wider Q2 Loss

With the conclusion of BioScrip (BIOS)-Option Care consolidation, the newly formed company gets its new name Option Care Health, Inc. under the ticker symbol BIOS.

Orthofix Medical (OFIX) Beats on Q2 Earnings, Margins Down

Orthofix Medical's (OFIX) Q2 performance across all business segments has been commendable, except for spinal implants.

Surging Earnings Estimates Signal Upside for SurModics (SRDX) Stock

SurModics (SRDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Surmodics (SRDX) Q3 Earnings Beat Estimates, Guidance Raised

Surmodics (SRDX) continues to gain from core Medical Devices unit, which saw significant contribution from the SurVeil deal with Abbott in Q3.

PRGO or SRDX: Which Is the Better Value Stock Right Now?

PRGO vs. SRDX: Which Stock Is the Better Value Option?

Here's Why You Should Hold on to Surmodics (SRDX) Stock Now

Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.

Are Options Traders Betting on a Big Move in Surmodics (SRDX) Stock?

Investors need to pay close attention to Surmodics (SRDX) stock based on the movements in the options market lately.

Zacks.com featured highlights include: LexinFintech, Veeco, Helen of Troy, Surmodics and Herman Miller

Zacks.com featured highlights include: LexinFintech, Veeco, Helen of Troy, Surmodics and Herman Miller